generalized epilepsy

(redirected from Generalised epilepsy)
Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Generalised epilepsy: focal epilepsy, generalized seizures

gen·er·al·ized ep·i·lep·sy

a major category of epilepsy syndromes characterized by one or more types of generalized seizures.

gen·er·al·ized ep·i·lep·sy

(jenĕr-ă-līzd epi-lep-sē)
Major category of epilepsy syndromes characterized by one or more types of generalized seizures.

gen·er·al·ized ep·i·lep·sy

(jenĕr-ă-līzd epi-lep-sē)
Major category of epilepsy syndromes characterized by one or more types of generalized seizures.
References in periodicals archive ?
Epilepsy-related diagnostic categories Diagnostic categories Frequency (N=69) % Generalised epilepsy 24 34.
Study participants in this subgroup mostly fitted into the diagnostic categories of generalised epilepsy (34.
perampanel), a convenient, once-daily epilepsy treatment, launches in Russia today, for primary generalised tonic-clonic (PGTC) seizures in adults and adolescents ([greater than or equal to]12 years) with idiopathic generalised epilepsy (IGE).
There are approximately 496, 920 people in Russia with epilepsy; one third of these have idiopathic generalised epilepsy and approximately 60% of these (103,525 people), will experience PGTC seizures.
Despite treatment, around 20% of people with idiopathic generalised epilepsy remain uncontrolled.
perampanel), for use as a once-daily, adjunctive therapy for primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (>12 years) with idiopathic generalised epilepsy (IGE).
Idiopathic generalised epilepsy affects the old, the young and everyone in between.
The sub analyses are part of the first randomised, Phase III, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adjunctive perampanel for the treatment of PGTC seizures in patients aged[greater than or equal to]12 years with idiopathic generalised epilepsy, 164 patients were randomised and included 81 patients who received perampanel and 81 patients who received placebo.
About Phase III study with adjunctive perampanel in idiopathic generalised epilepsy in patients with drug-resistant primary generalised tonic-clonic seizures by age, sex, race [sup.
Abstract Number Abstract details Perampanel Abstract number: #1362 Efficacy of adjunctive perampanel in idiopathic Monday 22 June generalised epilepsy: Subgroup analysis of patients with 12:30-13:15 absence and myoclonic seizures in a double-blind Screen B1, P3139 placebo-controlled Phase 3 trial Terence J O'Brien, Bernhard J Steinhoff, Haichen Yang, Antonio Laurenza, Anna Patten, Francesco Bibbiani Abstract number: #393 Efficacy of adjunctive perampanel in idiopathic Sunday 21 June generalised epilepsy patients with drug-resistant primary 14:14-16:15 generalised tonic-clonic seizures by age, sex, race: Hall A2, O2112 Double-blind PBO-controlled Phase 3 trial Bernhard J Steinhoff, Terence J O'Brien, Haichen Yang, Antonio Laurenza, Anna Patten, Francesco Bibbiani
In the first randomised, Phase III, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adjunctive perampanel for the treatment of primary generalised tonic-clonic (PGTC) seizures in patients aged[greater than or equal to]12 years with idiopathic generalised epilepsy, 164 patients were randomised and included 81 patients who received perampanel and 81 patients who received placebo.

Full browser ?